An intranasal ASO therapeutic targeting SARS-CoV-2
Despite approved vaccines and anti-virals to prevent and treat SARS-CoV-2 infection, there is a need for further development of efficient antiviral therapeutic strategy. Here, Zhu et al. develop locked nucleic acid antisense oligonucleotides (LNA ASOs) targeting the 5’ leader sequence of SARS-CoV-2...
Main Authors: | Chi Zhu, Justin Y. Lee, Jia Z. Woo, Lei Xu, Xammy Nguyenla, Livia H. Yamashiro, Fei Ji, Scott B. Biering, Erik Van Dis, Federico Gonzalez, Douglas Fox, Eddie Wehri, Arjun Rustagi, Benjamin A. Pinsky, Julia Schaletzky, Catherine A. Blish, Charles Chiu, Eva Harris, Ruslan I. Sadreyev, Sarah Stanley, Sakari Kauppinen, Silvi Rouskin, Anders M. Näär |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-32216-0 |
Similar Items
-
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
by: Xammy Nguyenla, et al.
Published: (2022-11-01) -
NanoSIMS Imaging Reveals the Impact of Ligand-ASO Conjugate Stability on ASO Subcellular Distribution
by: Emma Kay, et al.
Published: (2022-02-01) -
Individualized ASO therapy for rare diseases
Published: (2023-02-01) -
Amphibole–melt disequilibrium in silicic melt of the Aso-4 caldera-forming eruption at Aso Volcano, SW Japan
by: Hidemi Ishibashi, et al.
Published: (2018-08-01) -
RbH2AsO4
by: Berthold Stöger
Published: (2013-11-01)